NCT05235737View on ClinicalTrials.gov

The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

PHASE4RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

May 30, 2026

Conditions
Newly Diagnosed Glioblastoma
Interventions
DRUG

Pembrolizumab

Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol

DRUG

Pembrolizumab

Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol

Trial Locations (1)

41-200

RECRUITING

Wojciech Kaspera, Sosnowiec

All Listed Sponsors
collaborator

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice

OTHER

lead

Medical University of Silesia

OTHER